Amit Munshi

Amit Munshi is the Chief Executive Officer of Orna Therapeutics, a biotechnology company focused on developing circular RNA therapeutics.1 He is an industry veteran with over 30 years of experience in the pharmaceutical and biotechnology sectors.4

Career Highlights

Munshi recently became CEO of Orna Therapeutics following the company's strategic acquisition of ReNAgade Therapeutics, where he previously served as CEO.3 Prior to this, he was the President and CEO of Arena Pharmaceuticals Inc. (Nasdaq: ARNA), where he led a significant turnaround:

• Grew the company from a $300 million market cap to a late-stage clinical company
• Developed 37 programs, 4 drugs, and 11 indications
• Oversaw Arena's acquisition by Pfizer for $6.7 billion45

Other Leadership Roles

Munshi has held several other notable positions throughout his career:

• Co-founder and Chief Business Officer of Kythera Biopharmaceuticals Inc.
• General Manager of Amgen's European Nephrology Business Unit
• Held various positions at Amgen Inc., including roles in inflammation/immunology marketing5

Current Positions

In addition to his role at Orna Therapeutics, Munshi holds several other positions:

• Chairman of Zura Bio Limited (Nasdaq: ZURA)
• Chairman of the Board of Directors at Enterprise Therapeutics
• Board Member at Galecto, Inc.
• Co-founder of Oxeia Biopharmaceuticals2

Education

Munshi holds an MBA from The Peter Drucker Graduate School of Management at Claremont Graduate University and a BA in History and BS in Quantitative Economics from the University of California, Riverside.5

At Orna Therapeutics, Munshi is focused on advancing RNA-centric approaches to reshape the future of medicine, combining circular RNA expression technology with LNP-based RNA delivery systems to address challenges in drug development.3